NICARDIPINE HYDROCHLORIDE

Post-LOE

nicardipine hydrochloride

Chengdu New Radiomedicine

ANDAINJECTIONINJECTABLE

Approved

Sep 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Chengdu New Radiomedicine is 12. Approved for hypertension. First approved in 2024.

Drug data last refreshed 20h ago

Mechanism of Action

12.1 Mechanism of Action Nicardipine inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium…

Worked on NICARDIPINE HYDROCHLORIDE at Chengdu New Radiomedicine? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NICARDIPINE HYDROCHLORIDE

Mechanism of Action

Indications (1)